5 Reasons Why We Need to Support the Scientific Investigation of Medical Cannabis

MedicalMarijuanaSStock-Post 

Share this Post:

Nowadays, the only way to determine if medical marijuana will relieve your symptoms is to try it. And even if you do experience relief, you won’t know for certain whether it’s attributable to cannabis or to the placebo effect because there hasn’t yet been enough scientifically rigorous clinical research done on cannabis to make reliable assertions on its application and effectiveness.

While some claim this dearth of evidence is due to the reluctance of “big pharma” to pursue research because of the lack of potential profits, a bigger, more obvious reason is the fact that cannabis is illegal. And not just a little illegal — in the United States, cannabis is categorized by the federal government as a Schedule 1 drug, alongside heroin and GHB (more commonly known as the “date rape” drug). Schedule 1 drugs are characterized as having “no currently accepted medical treatment use” and a “lack of accepted safety for use.”

MedicalMarijuanaSStock-Post

So, in a Catch 22, research into the possible uses of marijuana as medicine is prevented by a law that has already concluded (despite a lack of research) that the plant has no medicinal value, and that mere possession makes one a criminal who is subject to jail time. Despite the White House recently eliminating a key restriction that has previously made medical marijuana research so difficult, the substance remains a Schedule 1 drug.

Why exactly is it so crucial for the United States to support actual scientific research of medical marijuana? These 5 reasons should provide some valuable insight:

1. Researchers Could Finally Use Science to Determine for Certain if Cannabis is Good Medicine
The best way to find out if something is effective medicine is through tightly controlled double (or triple) blind testing of statically relevant groups of individuals. Such experiments start by making a prediction, like “Ingesting 1000mg of dried daisy petals each day will result in the recipients having, on average, significantly fewer episodes of cold symptoms than groups receiving a placebo or a control group receiving neither high doses of daisy petals or a placebo (sugar pill).”
Ideally, no one—not the person administering the drug, not the subject being tested—knows who’s getting the daisy petals and who’s getting a placebo. After an appropriate period of time, the results are checked, preferably by a person who is shown just the statistics and who is entirely ignorant of the effect being tested (this is the golden “triple blind” condition).
If the group taking the high dose of daisy petals gets about the same number of colds as the placebo and control group, this indicates that high doses of daisy petals are probably useless in preventing colds. If, however, we found a statistically significant lowering of cold incidences in the daisy petal group, we would be justified in taking the research to the next level.
2.) Testing Takes Time and Repetition
Even if rigorous research reveals our drug does what we say it does, don’t expect everyone to agree. The scientific method is ruthless and filled with people lining up to prove us wrong. This is not just how it is, it’s absolutely necessary if we’re to reveal the truth. So the next step is to get our work published in respected, peer-reviewed journals, thereby openly inviting our colleagues to attack our methodology and our conclusions.
If we can survive that gauntlet, we next enter the bewildering maze that is the Food and Drug Administration approval process. No government agency is renowned for its speed and efficiency, and the FDA is no exception, regularly taking six years of deliberation and investigation of an experimental drug (and that’s on top of the previous work that’s gone into getting the drug in front of the FDA). This means that the overall process of bringing a new drug to market is typically eight to twelve years. That’s not only time-consuming, it’s really expensive.
3.) The Mountain of Evidence for the Efficacy of Medical Marijuana Remains Anecdotalm
This is where it’s appropriate to bring up the subject of “big pharma” not being interested in researching medical cannabis because there’s no money in it. Suppose it’s scientifically demonstrated that smoking cannabis is effective in decreasing symptoms of epilepsy. In that case, a patient can literally grow his or her own medicine in a flowerpot. No Pfizer or Merck needed.
But we’re not even that far yet. Even if the laws changed tomorrow and cannabis became legal in all 50 states, there would remain strong resistance from most physicians in prescribing it due to the lack of proof that it works better than existing treatments. Nearly all the evidence for the efficacy of medical marijuana remains anecdotal, which is to say, scientifically invalid.
4.) Many Physicians are Reluctant to Recommend Substances
This is not to say physicians aren’t interested in medical cannabis. Doctors want their patients to feel better, and if smoking the flowers of a plant can do that, so be it. Plus, patients are asking for it. But patients can be wrong. Think how many people still mistakenly believe that getting caught out in the rain causes pneumonia. Or that taking mega doses of Vitamin C prevents colds. Americans spend billions each year on entirely inactive homeopathic “medicines.”
Responsible doctors demand that the medicine they prescribe be absolutely uniform in strength and effect, and that’s not something that’s commonly available at this stage of developing cannabis as medicine.
5.) “For It to Work in the Medical World, It Has to Be Quantitative.”

 

Admirably, there are some businesses coming online that claim to address this lack of conformity by testing for levels of compounds such as THC and CBD to create a specific chemical profile. But at this stage, these tests can be unreliable, as a batch of the same strain from the same source may vary, depending, for example, on different growing conditions. On this situation, perhaps the world’s leading expert on cannabis, Dr. Raphael Mechoulam, commented: “Right now, people don’t know what they’re getting. For it to work in the medical world, it has to be quantitative. If you can’t count it, it’s not science.”

via Leafly

Share this Post:

Leave a Reply

Your email address will not be published. Required fields are marked *

Read more:
An Initiative To Legalize Marijuana In California To Appear On Nov. Ballot
The Actual Benefit of Medical Marijuana

Earlier this week the Obama administration reduced some severe restrictions on cannabis research, allowing for much more freedom to study...

Close